ASK REDCHAT ANYTHING ABOUT MINK THERAPEUTICS INC.
MiNK Therapeutics Inc. (NASDAQ: INKT)
Listen to this Section
$12.70
-0.0500
(
-0.39% )
0.1K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| AgenT-797 + botensilimab/balstilimabDetailsGastroesophageal adenocarcinomas, Gastric cancer |
Phase 2 |
| AgenT-797DetailsVirus-Induced Acute Respiratory Disease Syndrome |
Phase 1/2 |
| AgenT-797 +/- pembrolizumab/nivolumabDetailsCOVID-19, Acute respiratory distress syndrome, Solid tumor/s, Gastric cancer, Testicular cancer, Cancer, Non-small cell lung carcinoma |
Phase 1 |
| AgenT-797DetailsGraft-versus-host disease , Immune Disorders |
Phase 1 |
Market Data
|
| Open |
$12.70 |
| Previous Close |
$12.75 |
| Volume |
0.1K |
| Market Cap |
$63.57M |
| Day Range |
$12.61 - $13.10 |
| 52 Week Range |
$6.80 - $76.00 |
| Shares Outstanding |
4.98M |
| Change % |
-0.39% |
| Net Change |
▼ -0.0500 |
| Insider Ownership |
-0.02% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Medicinal Chemicals and Botanical Products |
| IPO Year | 2021 |
| Country | United States |
| Underwriter | Evercore ISI, William Blair, B. Riley Securities, Baird, more |
Insider Ownership Transactions
Total Amount Purchased:
-714,279.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-06-05 |
Sale |
-15077.00 |
WIINBERG ULF |
| 2024-06-05 |
Sale |
-17967.00 |
Corvese Brian |
| 2024-06-05 |
Sale |
-15454.00 |
Behner Peter |
| 2024-06-05 |
Sale |
-17841.00 |
Ryan Barbara |
| 2024-03-05 |
Sale |
-18816.00 |
Corvese Brian |
| 2024-03-05 |
Sale |
-18685.00 |
Ryan Barbara |
| 2024-03-05 |
Sale |
-16185.00 |
Behner Peter |
| 2024-03-05 |
Sale |
-15790.00 |
WIINBERG ULF |
| 2024-01-18 |
Sale |
-15000.00 |
van Dijk Marcus Antonius |
| 2024-01-18 |
Sale |
-500000.00 |
Buell Jennifer |